ASH 2020: Results of a study examining brentuximab vedotin for first line treatment of nodular sclerosis syncytial variant Hodgkin lymphoma.
Home / Resource Library / Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant